AN2 Therapeutics, Inc.
ANTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001880438
In the last 90 days, AN2 Therapeutics, Inc. insiders filed 1 open-market purchase and 5 sales; 66 institutions reported holding it in 13F filings for Q2 2026, worth $119.0M in total; no superinvestor holds it.
13F holders, Q3 2023
Institutional positions in AN2 Therapeutics, Inc. as of Sep 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 37
- +6 vs. Q2 2023
- Shares held
- 19.9M
- +8.19M (+69.8%) vs. Q2 2023
- Total value
- $320.3M
- +$220.4M (+220.7%) vs. Q2 2023
- New holders
- 14
- 12 more added
- Sold out
- 8
- 8 more reduced
Compare with Q2 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ANTX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 66 | $119.0M |
| Q1 2026 | 52 | $74.8M |
| Q4 2025 | 38 | $9.88M |
| Q3 2025 | 36 | $10.5M |
| Q2 2025 | 37 | $8.78M |
| Q1 2025 | 38 | $19.5M |
| Q4 2024 | 38 | $20.1M |
| Q3 2024 | 31 | $14.5M |
| Q2 2024 | 45 | $41.7M |
| Q1 2024 | 54 | $60.9M |
| Q4 2023 | 51 | $417.9M |
| Q3 2023 | 37 | $320.3M |
| Q2 2023 | 31 | $99.9M |
| Q1 2023 | 38 | $94.8M |
| Q4 2022 | 36 | $92.9M |
| Q3 2022 | 38 | $165.1M |
| Q2 2022 | 36 | $72.4M |
| Q1 2022 | 18 | $134.1M |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q3 2023
Shares, value and share of portfolio for each institution holding AN2 Therapeutics, Inc.; share changes are against Q2 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 5,551,295 | $89.3M | 1.76% | +1,777,778+47.1% | Added |
| TCG Crossover Management, LLC | 2,678,209 | $43.1M | 6.34% | +1,388,889+107.7% | Added |
| BVF Inc | 1,563,963 | $25.1M | 0.68% | 00.0% | Unchanged |
| Citadel Advisors LLC | 1,556,552 | $25.0M | 0.03% | +219,569+16.4% | Added |
| Frazier Life Sciences Management, L.P. | 1,388,889 | $22.3M | 1.48% | +1,388,889 | New |
| Janus Henderson Group PLC | 1,388,950 | $22.1M | 0.01% | +388,882+38.9% | Added |
| Avidity Partners Management LP | 1,089,400 | $17.5M | 0.71% | +432,200+65.8% | Added |
| Vanguard Group Inc | 939,891 | $15.1M | 0.00% | +387,092+70.0% | Added |
| Adage Capital Partners GP, L.L.C. | 905,556 | $14.6M | 0.03% | +905,556 | New |
| Octagon Capital Advisors LP | 867,575 | $14.0M | 2.46% | +146,675+20.3% | Added |
| Marshall Wace, LLP | 716,781 | $11.5M | 0.02% | +716,781 | New |
| Nantahala Capital Management, LLC | 356,789 | $5.74M | 0.73% | +356,789 | New |
| Invesco Ltd. | 187,897 | $3.02M | 0.00% | +187,897 | New |
| Citigroup Inc | 159,105 | $2.56M | 0.00% | +24,632+18.3% | Added |
| Monashee Investment Management LLC | 99,495 | $1.60M | 0.67% | −82,500−45.3% | Reduced |
| Geode Capital Management, LLC | 89,691 | $1.44M | 0.00% | +36,729+69.3% | Added |
| Victory Capital Management Inc | 52,100 | $837.8K | 0.00% | +52,100 | New |
| Alyeska Investment Group, L.P. | 50,000 | $804.0K | 0.01% | −48,426−49.2% | Reduced |
| Bridgeway Capital Management, LLC | 47,500 | $763.8K | 0.02% | +20,000+72.7% | Added |
| RMB Capital Management, LLC | 45,942 | $738.7K | 0.03% | +45,942 | New |
| BlackRock Inc. | 42,162 | $678.0K | 0.00% | +18,680+79.6% | Added |
| UBS Group AG | 41,046 | $660.0K | 0.00% | −8,627−17.4% | Reduced |
| Captrust Financial Advisors | 28,667 | $461.0K | 0.00% | +28,667 | New |
| Susquehanna International Group, LLP | 24,263 | $390.1K | 0.00% | +24,263 | New |
| Northern Trust Corp | 16,635 | $267.5K | 0.00% | +16,635 | New |
| State Street Corp | 15,402 | $247.7K | 0.00% | −2,700−14.9% | Reduced |
| Acuta Capital Partners, LLC | 13,300 | $213.9K | 0.16% | +13,300 | New |
| Barclays PLC | 3,170 | $51.0K | 0.00% | −23,904−88.3% | Reduced |
| Bank of America Corp | 3,095 | $49.8K | 0.00% | −9,121−74.7% | Reduced |
| Tower Research Capital LLC (TRC) | 3,045 | $49.0K | 0.00% | +3,045 | New |
| Morgan Stanley | 2,785 | $44.8K | 0.00% | −39,457−93.4% | Reduced |
| Heritage Wealth Advisors | 1,060 | $17.0K | 0.00% | +1,060 | New |
| FMR LLC | 670 | $10.8K | 0.00% | 00.0% | Unchanged |
| Rhumbline Advisers | 250 | $4.02K | 0.00% | −1,427−85.1% | Reduced |
| Advisor Group Holdings, Inc. | 200 | $3.22K | 0.00% | 00.0% | Unchanged |
| Federated Hermes, Inc. | 98 | $1.58K | 0.00% | +98 | New |
| Wells Fargo & Company | 62 | $997 | 0.00% | +27+77.1% | Added |
| Private Advisor Group, LLC | 0 | $0 | 0.00% | −67,500−100.0% | Sold out |
| Goldman Sachs Group Inc | 0 | $0 | 0.00% | −39,107−100.0% | Sold out |
| Millennium Management LLC | 0 | $0 | 0.00% | −24,242−100.0% | Sold out |
| Qube Research & Technologies Ltd | 0 | $0 | 0.00% | −18,361−100.0% | Sold out |
| Y-Intercept (Hong Kong) Ltd | 0 | $0 | 0.00% | −14,040−100.0% | Sold out |
| Integrated Wealth Concepts LLC | 0 | $0 | 0.00% | −12,500−100.0% | Sold out |
| Royal Bank of Canada | 0 | $0 | 0.00% | −186−100.0% | Sold out |
| New York State Common Retirement Fund | 0 | $0 | 0.00% | −101−100.0% | Sold out |